Skip to main content
Psych Congress  

Concerns from Community Mental Health Center (CMHC) Patients Regarding Drug-Induced Movement Disorders: Impact on Functioning and Treatment Beliefs

Authors  

Allison Stiles, MA, LPC, CPMC-Director of Technology and Behavioral Health Integration, CommonGround Program; Ericha Franey, PhD-Neurocrine Biosciences, Inc.; Edward Goldberg, MD-Neurocrine Biosciences, Inc.; Leslie Lundt, MD-Neurocrine Biosciences, Inc.; Chuck Yonan, PharmD-Neurocrine Biosciences, Inc.; Rahul Dhanda, PhD-Neurocrine Biosciences, Inc.

Sponsor  
Neurocrine Biosciences, Inc.

Background: Drug-induced movement disorders (DIMDs) may occur in patients treated with antipsychotics. The CommonGround Program supports the recovery and healing of psychiatric outpatients through tools which facilitate better patient-doctor communication regarding psychiatric symptoms, DIMDs, and the effectiveness of treatment.

Methods: Patients’ responses to CommonGround’s web-based waiting-room questionnaire were analyzed in patients who responded “yes” to having concerns about developing DIMDs (“MD-YES”) and those who responded “no” to this question (“MD-NO”). These groups were compared descriptively to assess the potential effects of DIMD concerns on self-reported functioning and beliefs about prescribed psychiatric medications.

Results: Of 7874 responding patients, 312 (4.0%) and 7562 (96.0%) were in the MD-YES and MD-NO subgroups, respectively. A higher percentage of MD-YES patients reported “poor”/“not so good” ability to keep up with daily responsibilities (21.2% vs 15.2% vs MD-NO), along with low energy levels (37.1% vs 26.3% for MD-NO), bothersome thoughts/beliefs/fears (30.5% vs 16.0%), and nervousness/anxiety (35.3% vs 27.5%) “all”/“most” of the time. MD-YES patients were also more likely to wonder about stopping their medications (9.3% vs 0.6% for MD-NO) and were concerned about side effects such as sleepiness (31.4% vs 3.9%) and weight gain (37.2% vs 5.7%).

Conclusion: Patients from community mental health centers who were concerned about developing DIMDs tended to express problems with daily functioning and concerns about their psychiatric medications. For these patients, recognizing their fears and concerns may help clinicians discuss treatment options for DIMDs, which could increase patient confidence, encourage adherence to current psychiatric medications, and potentially improve outcomes.

Back to Top